Introduction
There is an inverse relationship between plasma HDL levels and the incidence ofatherosclerotic cardiovascular disease ( 1 ). One ofthe factors influencing HDL levels is the plasma choles- apoA-I. Homozygous genetic deficiency of CETP caused by a point mutation in the intron 14 splice donor of the 16 exon CETP gene (2) results in profound increases in HDL CE and apo A-I (3) (4) (5) (6) . However, heterozygotes with this condition show only moderate reductions of CETP activity and small increases in total HDL cholesterol (3) (4) (5) (6) . The CETP gene splicing defect is a fairly common cause of increased HDL in the Japanese population (3) (4) (5) (6) . We now describe a new CETP gene missense mutation that appears to have dominant effects on HDL levels.
Methods
DNA was extracted from peripheral blood cells of the two probands and analyzed by PCR. Each exon was amplified using paired synthetic oligodeoxyribonucleotides complementary to the human CETP gene sequence (7) . The paired nucleotide sequences of oligonucleotide primers corresponded to 5'-and 3'-flanking intronic sequence of target exons, respectively. The primers used to amplify exon 15 and flanking sequences were 5'CTCAAGCTTTGGGGCAGAAGGGAAT3', 5'CAGGAATTCTGTCTGGGCCTTCTCTC3', generating a 392-bp fragment. The products of the PCR reaction were subcloned into pBluescriptll SK-(Stratagene, La Jolla, CA). Several isolated clones were sequenced on both strands by the dideoxy chain termination method.
Mutagenesis and cellular expression. Transient expression of CETP in COS7 cell and assays for CETP mass and activity in cell media were performed as described previously (8), using 5 
Results
derived from the normal allele ( Fig. 1 C) . These findings confirm that the subject is heterozygous for this mutation. The probands' markedly increased HDL and severely decreased CETP mass and activity suggested a dominant effect of the The probands are two unrelated elderly healthy females who have no evidence of atherosclerosis. Their plasma lipids and apoproteins are shown in Table I . Both had markedly increased plasma HDL cholesterol, primarily in the HDL-2 fraction, and increased plasma apo A-I but not apo A-II. Plasma apo E, apo C-II and apo C-III were also increased and plasma apo B was normal. These change are typical of those observed in subjects with homozygous CETP deficiency caused by an intron 14 gene splicing defect (2-6). Homozygotes have no detectable plasma CETP mass or activity. By contrast, the probands had reduced but detectable CETP mass and activity (Table I ). The CETP concentration was reduced to 17-26% ofnormal and the activity to 5-7% of normal. Both probands showed a marked decrease in CETP specific activity. Heterozygotes for the CETP gene splicing defect (n = 20) have mean HDL cholesterols of 68 mg/dl (range = 40-107 mg/dl) and have -60% ofnormal plasma CETP concentration, and normal CETP specific activity (3, 5) . These findings suggested that the probands might have a different CETP gene mutation. Southern blotting of the probands' DNA using the CETP cDNA (9) revealed no major rearrangements or deletions of the CETP gene. However, sequencing of all exons and exon/ intron junctions ofthe CETP gene showed that both probands are heterozygous for a CETP missense mutation (442 D:G) (one is shown in Fig. 1 A) . No other abnormalities were detected. This mutation is found in exon 15 ofthe 16-exon CETP gene ( Fig. 1 B) (7) . The G:A transition leads to loss of a Taq I site ( Fig. 1 C) . Taq I digestion of PCR amplified exon 15 and flanking DNA sequences showed that one allele of the proband's CETP gene had lost the Taql site. This results in an additional 76-bp fragment seen just above the 72-bp fragment missense mutation. However, other family members were not available for study.
To ascertain if the missense mutation influences CETP function, the mutant cDNA was prepared by site-directed mutagenesis and transiently expressed in Cos cells (Table II) . The activity of CETP accumulating in media was measured using isotopically labeled lipoprotein substrates. In seven different cellular transfections, the mutant cDNA produced 30±4% of wild type CETP activity. Analysis of CETP concentration and specific activity in media indicated both decreased secretion and specific activity of the mutant (Table II) . These findings confirm that the mutation has moderate effects on CETP secretion and specific activity, but they do not explain the probands' phenotype, since the wild type allele should contribute 2 50% of normal CETP mass and activity.
To assess a possible dominant inhibitory effect of the mutant protein, cellular media containing mutant and wild type protein were mixed in different proportions and CETP activity was assessed (Fig. 2) . The resulting activity was simply a weighted average ofwild type and mutant activities. Increasing amounts ofwild type or mutant alone gave rise to the expected linear increase in activity (not shown). The mixing result did not deviate significantly from the activity predicted for no inhibition of wild type activity (Fig. 2, dashed line) .
However, when equimolar mutant and wild type cDNAs were cotransfected in Cos cells, secreted CETP activity was only 36±6% ofwild type, and was similar to that resulting from expression of mutant alone (Table II) . This result is different to the predicted value of65% obtained by mixing wild-type and mutant protein (Fig. 2) . Thus, there is a dominant inhibitory effect of the mutant on the wild type cDNA during cellular expression. Analysis of CETP activity and mass in media showed that cotransfection of mutant with wild type led to significant reductions in both CETP concentration and specific activity (Table II) . To see if the lower activities produced by the mutant might be caused by differences in cell transfection efficiencies or mRNA levels, CETP mRNA was determined in cells pooled from three separate transfection experiments (which had given activity results similar to these shown in Table II). This assay showed similar abundance ofCETP mRNA in the three different transfection conditions (Fig. 3) . Quantitation of CETP mRNA by comparison with standards showed abundances of 94 pg/mg total RNA (mutant), 104 pg/mg (mutant and wild type) and 100 pg/mg (wild type), confirming that the low activity ofthe mutant and its dominant inhibitory effects were not caused by differences in cell transfection efficiency or mRNA expression. (10) . The CETP mRNA was determined by RNase protection assay (10) using 50 ,ug of total RNA and a riboprobe containing the last 28 codons plus 58 nucleotides ofthe 3'-untranslated region ofthe human CETP mRNA. This probe recognizes wild type and mutant RNA identically. The positive control was 20 ,ug hepatic total RNA from high expressing human CETP transgenic mice. The standard curve was constructed from 3H-labeled sense cRNA (10) . The standards and samples were quantitated by gel scanning with a Molecular Dynamics laser densitometer. * CETP was purified from Chinese hamster ovary cell media and concentrated to 1 mg/ml by centrifugation in filters (Centricon-30; Amicon, Beverly, MA). Purified CETP was diluted in 10 mM potassium phosphate, pH 7.4/0.1 mM DTT for use in a laser light scattering instrument (model dp-801; Biotage Inc., Charlottesville, VA) at room temperature (12) . Sample volumes of 250 Ml were filtered and injected manually into the instrument. The estimated molecular weight of the sample was calculated from its measured hydrodynamic radius and those of a series of well-characterized globular proteins.
Varying dilutions of CETP were prepared, analysis of more dilute protein samples (<125 gg/ml) were limited by the sensitivity of the instrument. At all concentrations tested, the protein formed a monodisperse solution (hydrodynamic radius, RH= 4.94 ± 0.10 nm).
(2). Two heterozygotes for the missense mutation have marked reductions in plasma CETP activity and dramatic increases in HDL cholesterol, suggesting that the mutant has dominant expression in vivo. Although confirmation must await the identification and characterization ofadditional subjects with the mutation, cellular expression experiments showed that the 442 D:G mutant CETP has dominant inhibitory effects on the secretion and activity of the wild type, strongly supporting the hypothesis of dominant expression. Recently, additional subjects with this mutation have been found by other investigators, and preliminary results are consistent with a dominant effect on HDL levels (A. Inazu, J. Koizumi, and H. Mabuchi, personal communication). A dominantly acting CETP mutant has interesting implications for the mechanisms of CETP secretion and activity, as well as for the potential impact ofCETP genetic deficiency states on HDL levels in population studies. The markedly increased HDL in the two probands was matched by a severe reduction in CETP activity (Table I (Table II) . The cell expression experiments predict dominant inhibition of CETP secretion and reduced plasma CETP specific activity in vivo. Since heterozygotes with the splicing defect have -60% of normal CETP mass, and normal CETP specific activity (3), both dominant inhibition of CETP production and specific activity are probably occurring in the probands (Table II) . In the probands' plasma the reduced CETP concentration and specific activity gave a net reduction in CETP activity to -5% of normal in one proband and 7% in the other, somewhat less than the value of 36% predicted from the cotransfection experiment (Table II) (15, 16) . Purified plasma CETP is known to self-associate in native gels (10) , and purified recombinant CETP was shown to be dimeric in solution by quasielastic light scattering in the present study. Although these measurements were conducted at higher concentrations than exist in plasma (3), CETP also readily forms dimers at plasma concentrations as shown by cross-linking studies (C. Bruce and A. Tall, unpublished observation). Furthermore, proteins become highly concentrated in the cellular secretory pathway ( 17) . The dominant inhibition of wild type by mutant CETP (Table II) suggests that CETP multimers may be formed during cellular secretion, and could be involved in the lipid transfer mechanism. The inability to observe this effect during simple mixing (Fig. 2) (20) .
The CETP gene splicing defect (2) is common in Japan. About 1% of the Japanese population, and 1 1-17% of subjects with HDL cholesterols > 60 mg/dl, are heterozygotes (21, 22) . The present findings suggest that some CETP missense mutations will cause pronounced increases in HDL in the heterozygous state. Although their prevalence is unknown, missense mutations with a strong effect on HDL, together with a common splicing defect with mild effects on HDL (2-6), could result in genetic CETP deficiency states having a significant impact on the epidemiology of HDL in Japan. Genetic CETP deficiency might also interact synergistically with environmen-tal factors that decrease CETP, such as alcohol intake (23, 24) . A high frequency of genetic CETP deficiency states could reflect a biological advantage, such as the resistance to endotoxin conferred by increased HDL levels (25). It is also of interest to note that the first major epidemiological study documenting a protective effect of increased HDL on coronary artery disease was performed in men of Japanese descent living in Hawaii ( 1).
